Active Ingredient History
Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Graft vs Host Disease (Phase 1)
Kidney Diseases (Phase 1)
Kidney Failure, Chronic (Phase 2)
Kidney Transplantation (Phase 2)
Leukemia (Phase 2)
Lymphoma (Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1)
Lymphoproliferative Disorders (Phase 1)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasms (Phase 1)
Psoriasis (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue